Seeking Alpha

Advaxis to hold End-of-Phase 2 meeting with FDA

  • The FDA agrees to an End-of-Phase 2 meeting with Advaxis (ADXS) to discuss the clinical results of its lead cancer immunotherapy candidate ADXS-HPV. The purpose of the meeting is to assess what needs to be done to move into a Phase 3 trial.
  • ADXS-HPV is being studied for the treatment of HPV-related cancers. The FDA designated it an Orphan Drug for Stage II-IV invasive cervical cancer.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: